Physician profile
John Gambrill
NPI 1710033022
$1,730.17
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $153 · 2021: $241 · 2022: $410 · 2023: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $245.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $196.44 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Amgen INC. | $188.09 | 2019-2020 | |
| Amarin Pharma, INC. | $146.87 | 2019 | |
| Abbvie INC. | $124.58 | 2022 | |
| Novo Nordisk INC | $119.56 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $106.31 | 2022-2023 | Mounjaro, Trulicity |
| Sun Pharmaceutical Industries INC. | $106.09 | 2019-2023 | Cequa |
| Akcea Therapeutics, INC. | $89.09 | 2019 | |
| Alcon Vision LLC | $68.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.00 | 2019-2023 | |
| Genzyme Corporation | $52.40 | 2021 | |
| Arbor Pharmaceuticals, INC. | $45.00 | 2019-2020 | |
| Exact Sciences Corporation | $37.72 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $27.20 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.25 | 2022 | |
| Allergan, INC. | $20.16 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.80 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gambrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.